Brief: Genfit Puts On Hold All Its Phase 1 Trials Due To COVID-19 Pandemic

Genfit SA

31/03/2020 08:15

March 31 (Reuters) - GENFIT SA  GNFT.PA :
    * GENFIT: UPDATE ON REGULATORY AND CLINICAL ACTIVITIES AMID
THE
COVID-19 PANDEMIC
    * WE DO NOT FORESEE ANY ISSUES WITH SUPPLY OF RAW MATERIALS
AND
PRODUCTION OF COMMERCIAL BATCHES
    * OUR PARTNERS AND THE GENFIT TEAMS HAVE PUT IN PLACE
CONTINGENCY
PLANS TO MANAGE THE OPERATIONAL ASPECTS OF OUR ONGOING AND
PLANNED TRIALS, EVEN UNDER THE CURRENT CONDITIONS
    * ALL PHASE 1 TRIALS – WHICH INCLUDE PHARMACOKINETIC, FOOD
EFFECT
AND BIOEQUIVALENCE STUDIES – HAVE BEEN PUT ON HOLD
    * ALL SUPPORTING ACTIVITIES PERTAINING TO CONTINUATION OF
ONGOING
STUDIES OR INITIATION OF NEW STUDIES WILL CONTINUE IN ORDER TO
MINIMIZE POTENTIAL DELAYS WHEN PANDEMIC CRISIS SUBSIDES
    * WE HAVE IMPLEMENTED APPROPRIATE MEASURES TO ENSURE THE
SAFETY OF
PATIENTS WHO ARE ALREADY PARTICIPATING IN THE RESOLVE-IT STUDY:
VIRTUAL CLINIC VISITS, LOCAL LABORATORY ASSESSMENT, HOME
DELIVERY OF STUDY DRUG, AND HALTING THE SCREENING OF NEW
PATIENTS
    * AT THIS STAGE WE DO NOT ANTICIPATE ANY SUPPLY DISRUPTION
FOR ANY
OF OUR CURRENT OR PLANNED STUDIES

Source text for Eikon:  ID:nGNX3cdKkb 
Further company coverage:  GNFT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))